Debt-to-equity in % of Cytek Biosciences, Inc. from Q1 2022 to Q3 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Cytek Biosciences, Inc. quarterly Debt-to-equity history and change rate from Q1 2022 to Q3 2025.
  • Cytek Biosciences, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was 28.7 %, a 11.4% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Cytek Biosciences, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 28.7 +2.94 +11.4% 30 Sep 2025
Q2 2025 27.8 +2.73 +10.9% 30 Jun 2025
Q1 2025 26.3 +1.31 +5.25% 31 Mar 2025
Q4 2024 25.8 +1.23 +5% 31 Dec 2024
Q3 2024 25.7 +2.04 +8.62% 30 Sep 2024
Q2 2024 25.1 +2.7 +12% 30 Jun 2024
Q1 2024 25 +3.51 +16.4% 31 Mar 2024
Q4 2023 24.6 +4.31 +21.2% 31 Dec 2023
Q3 2023 23.7 +5.34 +29.1% 30 Sep 2023
Q2 2023 22.4 +5.87 +35.5% 30 Jun 2023
Q1 2023 21.4 +1.99 +10.2% 31 Mar 2023
Q4 2022 20.3 31 Dec 2022
Q3 2022 18.3 30 Sep 2022
Q2 2022 16.5 30 Jun 2022
Q1 2022 19.5 31 Mar 2022
* An asterisk sign (*) next to the value indicates that the value is likely invalid.